A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Phase 3 Completed 488 enrolled Chongqing Claruvis Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is a Multi-center, Open-label Study on the Efficacy and Safety of Multiple Treatments with Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines. The study has been designed to evaluate the long-term safety, tolerability, efficacy , maintain time and immunogenicity of multiple treatments with Recombinant Botulinum Toxin Type A for Injection (YY001) in the treatment of moderate to severe glabellar lines.

Timeline

Start: 2024-03-19
Primary completion: 2025-08-25
Completion: 2025-08-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Recombinant Botulinum Toxin Type A	Protein / enzyme biologic	20 iu	—

Indications

No indication recorded.